Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy

Jacqueline A. Hawkins-Salsbury, Lauren Shea, Xuntian Jiang, Daniel A. Hunter, A. Miguel Guzman, Adarsh S. Reddy, Elizabeth Y. Qin, Yedda Li, Steven J. Gray, Daniel S. Ory, Mark S. Sands

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Globoid cell leukodystrophy (GLD, Krabbe disease) is a lysosomal storage disease (LSD) caused by a deficiency in galactocerebrosidase (GALC) activity. In the absence of GALC activity, the cytotoxic lipid, galactosylsphingosine (psychosine), accumulates in the CNS and peripheral nervous system. Oligodendrocytes and Schwann cells are particularly sensitive to psychosine, thus leading to a demyelinating phenotype. Although hematopoietic stem-cell transplantation provides modest benefit in both presymptomatic children and the murine model (Twitcher), there is no cure for GLD. In addition, GLD has been relatively refractory to virtually every experimental therapy attempted. Here, Twitcher mice were simultaneously treated with CNS-directed gene therapy, substrate reduction therapy, and bone marrow transplantation to target the primary pathogenic mechanism (GALC deficiency) and two secondary consequences of GALC deficiency (psychosine accumulation and neuroinflammation). Simultaneously treating multiple pathogenic targets resulted in an unprecedented increase in life span with improved motor function, persistent GALC expression, nearly normal psychosine levels, and decreased neuroinflammation. Treating the primary pathogenic mechanism and secondary targets will likely improve therapeutic efficacy for other LSDs with complex pathological and clinical presentations.

Original languageEnglish (US)
Pages (from-to)6495-6505
Number of pages11
JournalJournal of Neuroscience
Volume35
Issue number16
DOIs
StatePublished - Jan 1 2015

Fingerprint

Psychosine
Globoid Cell Leukodystrophy
Galactosylceramidase
Lysosomal Storage Diseases
Therapeutics
Lysergic Acid Diethylamide
Investigational Therapies
Hematopoietic Stem Cell Transplantation
Schwann Cells
Oligodendroglia
Peripheral Nervous System
Bone Marrow Transplantation
Genetic Therapy
Phenotype
Lipids

Keywords

  • Dysmyelination
  • Gene therapy
  • Globoid cell leukodystrophy
  • Krabbe disease
  • Lysosomal storage disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Hawkins-Salsbury, J. A., Shea, L., Jiang, X., Hunter, D. A., Miguel Guzman, A., Reddy, A. S., ... Sands, M. S. (2015). Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. Journal of Neuroscience, 35(16), 6495-6505. https://doi.org/10.1523/JNEUROSCI.4199-14.2015

Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. / Hawkins-Salsbury, Jacqueline A.; Shea, Lauren; Jiang, Xuntian; Hunter, Daniel A.; Miguel Guzman, A.; Reddy, Adarsh S.; Qin, Elizabeth Y.; Li, Yedda; Gray, Steven J.; Ory, Daniel S.; Sands, Mark S.

In: Journal of Neuroscience, Vol. 35, No. 16, 01.01.2015, p. 6495-6505.

Research output: Contribution to journalArticle

Hawkins-Salsbury, JA, Shea, L, Jiang, X, Hunter, DA, Miguel Guzman, A, Reddy, AS, Qin, EY, Li, Y, Gray, SJ, Ory, DS & Sands, MS 2015, 'Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy', Journal of Neuroscience, vol. 35, no. 16, pp. 6495-6505. https://doi.org/10.1523/JNEUROSCI.4199-14.2015
Hawkins-Salsbury, Jacqueline A. ; Shea, Lauren ; Jiang, Xuntian ; Hunter, Daniel A. ; Miguel Guzman, A. ; Reddy, Adarsh S. ; Qin, Elizabeth Y. ; Li, Yedda ; Gray, Steven J. ; Ory, Daniel S. ; Sands, Mark S. / Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. In: Journal of Neuroscience. 2015 ; Vol. 35, No. 16. pp. 6495-6505.
@article{bad1436b8c594a3ea20796e572b401af,
title = "Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy",
abstract = "Globoid cell leukodystrophy (GLD, Krabbe disease) is a lysosomal storage disease (LSD) caused by a deficiency in galactocerebrosidase (GALC) activity. In the absence of GALC activity, the cytotoxic lipid, galactosylsphingosine (psychosine), accumulates in the CNS and peripheral nervous system. Oligodendrocytes and Schwann cells are particularly sensitive to psychosine, thus leading to a demyelinating phenotype. Although hematopoietic stem-cell transplantation provides modest benefit in both presymptomatic children and the murine model (Twitcher), there is no cure for GLD. In addition, GLD has been relatively refractory to virtually every experimental therapy attempted. Here, Twitcher mice were simultaneously treated with CNS-directed gene therapy, substrate reduction therapy, and bone marrow transplantation to target the primary pathogenic mechanism (GALC deficiency) and two secondary consequences of GALC deficiency (psychosine accumulation and neuroinflammation). Simultaneously treating multiple pathogenic targets resulted in an unprecedented increase in life span with improved motor function, persistent GALC expression, nearly normal psychosine levels, and decreased neuroinflammation. Treating the primary pathogenic mechanism and secondary targets will likely improve therapeutic efficacy for other LSDs with complex pathological and clinical presentations.",
keywords = "Dysmyelination, Gene therapy, Globoid cell leukodystrophy, Krabbe disease, Lysosomal storage disease",
author = "Hawkins-Salsbury, {Jacqueline A.} and Lauren Shea and Xuntian Jiang and Hunter, {Daniel A.} and {Miguel Guzman}, A. and Reddy, {Adarsh S.} and Qin, {Elizabeth Y.} and Yedda Li and Gray, {Steven J.} and Ory, {Daniel S.} and Sands, {Mark S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1523/JNEUROSCI.4199-14.2015",
language = "English (US)",
volume = "35",
pages = "6495--6505",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "16",

}

TY - JOUR

T1 - Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy

AU - Hawkins-Salsbury, Jacqueline A.

AU - Shea, Lauren

AU - Jiang, Xuntian

AU - Hunter, Daniel A.

AU - Miguel Guzman, A.

AU - Reddy, Adarsh S.

AU - Qin, Elizabeth Y.

AU - Li, Yedda

AU - Gray, Steven J.

AU - Ory, Daniel S.

AU - Sands, Mark S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Globoid cell leukodystrophy (GLD, Krabbe disease) is a lysosomal storage disease (LSD) caused by a deficiency in galactocerebrosidase (GALC) activity. In the absence of GALC activity, the cytotoxic lipid, galactosylsphingosine (psychosine), accumulates in the CNS and peripheral nervous system. Oligodendrocytes and Schwann cells are particularly sensitive to psychosine, thus leading to a demyelinating phenotype. Although hematopoietic stem-cell transplantation provides modest benefit in both presymptomatic children and the murine model (Twitcher), there is no cure for GLD. In addition, GLD has been relatively refractory to virtually every experimental therapy attempted. Here, Twitcher mice were simultaneously treated with CNS-directed gene therapy, substrate reduction therapy, and bone marrow transplantation to target the primary pathogenic mechanism (GALC deficiency) and two secondary consequences of GALC deficiency (psychosine accumulation and neuroinflammation). Simultaneously treating multiple pathogenic targets resulted in an unprecedented increase in life span with improved motor function, persistent GALC expression, nearly normal psychosine levels, and decreased neuroinflammation. Treating the primary pathogenic mechanism and secondary targets will likely improve therapeutic efficacy for other LSDs with complex pathological and clinical presentations.

AB - Globoid cell leukodystrophy (GLD, Krabbe disease) is a lysosomal storage disease (LSD) caused by a deficiency in galactocerebrosidase (GALC) activity. In the absence of GALC activity, the cytotoxic lipid, galactosylsphingosine (psychosine), accumulates in the CNS and peripheral nervous system. Oligodendrocytes and Schwann cells are particularly sensitive to psychosine, thus leading to a demyelinating phenotype. Although hematopoietic stem-cell transplantation provides modest benefit in both presymptomatic children and the murine model (Twitcher), there is no cure for GLD. In addition, GLD has been relatively refractory to virtually every experimental therapy attempted. Here, Twitcher mice were simultaneously treated with CNS-directed gene therapy, substrate reduction therapy, and bone marrow transplantation to target the primary pathogenic mechanism (GALC deficiency) and two secondary consequences of GALC deficiency (psychosine accumulation and neuroinflammation). Simultaneously treating multiple pathogenic targets resulted in an unprecedented increase in life span with improved motor function, persistent GALC expression, nearly normal psychosine levels, and decreased neuroinflammation. Treating the primary pathogenic mechanism and secondary targets will likely improve therapeutic efficacy for other LSDs with complex pathological and clinical presentations.

KW - Dysmyelination

KW - Gene therapy

KW - Globoid cell leukodystrophy

KW - Krabbe disease

KW - Lysosomal storage disease

UR - http://www.scopus.com/inward/record.url?scp=84929340483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929340483&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.4199-14.2015

DO - 10.1523/JNEUROSCI.4199-14.2015

M3 - Article

VL - 35

SP - 6495

EP - 6505

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 16

ER -